News

Article

ALLO-715 Found to Be Effective Against Multiple Myeloma

CAR T-cell therapy associated with greater anti-cancer activity in treating multiple myeloma.

A pair of allogeneic chimeric antigen receptor (CAR) T-cell therapies, ALLO-715 and ALLO-647, may be safe and effective treatments for patients with multiple myeloma, according to a presentation at the 62nd American Society of Hematology Annual Meeting and Exposition.

ALL0-715 is a genetically modified anti-BCMA AlloCAR T cell product in which the TCR alpha constant gene is disrupted in order to reduce the risk of graft-versus-host disease. The C52 gene is disrupted with Talen technology to the permit the use of ALLO-647, which is an anti-CD52 mAbm for selective and prolonged host lymphodepletion, according to the study.

The phase 1 open-label trial was made up of 19 patients who have received 3 or more prior lines of therapy, including a proteasome inhibitor, immunomodulator, and an anti-CD38 monoclonal antibody. All participants must be refractory to their last line of treatment. Patients received lymphodepletion followed by ALLO-715 at 1 of 4 dose levels in a 3+3 escalation design.

According to the study, a higher dose of ALLO-715 was associated with greater anti-cancer activity. Of the 19 patients, 15 received ALLO-715 at 3 dose levels. Eighty percent of responders were still in response at the time of data cutoff. Cytokine release syndrome was reported in 24% of patients. Over the course of the trial, 1 death occurred after the patient went into respiratory failure, but it was considered related to conditioning, according to the study.

Early data suggest that ALLO-715 and ALLO-647 have manageable safety profiles. Enrollment in ongoing cohorts with higher ALLO-715 and ALLO-647 are ongoing. According to the study, ALLO-715 showed evidence of clinical activity in the allogenic setting in patients with relapsed/refractory multiple myeloma.

REFERENCE

Mailankody, S. et al. 129 Universal: An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple Myeloma [Abstract] December 5, 2020. Accessed December 14, 2020. https://ash.confex.com/ash/2020/webprogram/Paper140641.html.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Related Videos
Cardiovascular disease doctor or cardiologist holding red heart in clinic or hospital exam room office for csr professional medical service, cardiology health care and world heart health day concept - Image credit: Chinnapong | stock.adobe.com
Image credit: AwieDarwis | stock.adobe.com
Image credit: viperagp | stock.adobe.com
Inflammation concept, inflammated human tissues 3d rendering - Image credit: picture-waterfall | stock.adobe.com